6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report ofForeign Private Issuer

Pursuant to Rule 13a-16 or15d-16 under

the Securities Exchange Act of 1934

For the month of January, 2024

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant’s name into English)

6 TideStreet, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended January 31, 2024, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:

During the month ended January 31, 2024, the Company repurchased an aggregate of 1,586,857 Ordinary Shares. As of January 31, 2024, the Company’s issued share capital was 289,468,159 shares, 19,201,285 of which were held in treasury, resulting in total voting rights in the Company of 270,266,874 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

January 2, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5020285.html

January 3, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5021785.html

January 4, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5023116.html

January 5, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5024534.html

January 8, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5026060.html

January 9, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5027519.html

January 10, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5028977.html

January 11, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5030521.html

January 12, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5031994.html

January 15, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5033545.html

January 16, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5035014.html

January 17, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5036591.html

January 18, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5038077.html

January 19, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5039559.html

January 22, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5041268.html

January 23, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5042765.html

January 24, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5044274.html

January 25, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5045798.html

January 26, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5048616.html

January 29, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5048832.html

January 30, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5050375.html

January 31, 2024: https://data.fca.org.uk/artefacts/NSM/RNS/5051986.html

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.